Physician profile
Hunter Green
NPI 1407586779
$487.62
in general payments reported to CMS, 2019-2025
13 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $37.35 · 2024: $15.92 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $73.03 | 2025 | |
| Glaxosmithkline, LLC. | $57.96 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $57.46 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $51.23 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $48.13 | 2025 | Airsupra, Breztri |
| Amgen INC. | $47.50 | 2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $42.87 | 2025 | Verquvo, Lagevrio, Capvaxive |
| Pfizer INC. | $30.67 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2025 | |
| Alexion Pharmaceuticals, INC. | $15.92 | 2024 | Strensiq |
| Organon LLC | $15.44 | 2023 | Nexplanon |
| Lilly USA, LLC | $14.05 | 2025 | Zepbound |
| Sumitomo Pharma America, INC. | $13.98 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.